(Q43662494)

English

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism

scientific article published in July 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism (English)

1 reference

Europe PubMed Central

25 November 2017

0 references

1 reference

based on heuristic

inferred from title

medroxyprogesterone acetate

1 reference

based on heuristic

inferred from title

author name string

Lobo RA

1

1 reference

Europe PubMed Central

25 November 2017

Bush T

2

1 reference

Europe PubMed Central

25 November 2017

Carr BR

3

1 reference

Europe PubMed Central

25 November 2017

Pickar JH

4

1 reference

Europe PubMed Central

25 November 2017

language of work or name

0 references

publication date

1 July 2001

1 reference

Europe PubMed Central

25 November 2017

Fertility and Sterility

1 reference

Europe PubMed Central

25 November 2017

76

1 reference

Europe PubMed Central

25 November 2017

13-24

1 reference

Europe PubMed Central

25 November 2017

1

1 reference

Europe PubMed Central

25 November 2017

Healthcare use among U.S. women aged 45 and older: total costs and costs for selected postmenopausal health risks.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Is there a menopausal metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Plasma cholesteryl ester fatty acid composition, insulin sensitivity, the menopause and hormone replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Lipids, clotting factors, and diabetes: endogenous risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Guide to Preventive Cardiology for Women.AHA/ACC Scientific Statement Consensus panel statement

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Menopause and risk of cardiovascular disease: the Framingham study.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

The role of hormone replacement therapy in the prevention of postmenopausal heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Hormone replacement therapy in the prevention and treatment of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Postmenopausal hormone therapy and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Determinants of long-term hormone replacement therapy and reasons for early discontinuation

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Personal perspective on low-dosage estrogen therapy for postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Venous thrombo-embolism and hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Plasma lipoprotein levels as predictors of cardiovascular death in women.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Lipoprotein(a) as a risk factor for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Cardiovascular implications of the factor V Leiden mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Menopause-related changes in lipoproteins and some other cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901829-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0015-0282(01)01829-5

1 reference

Europe PubMed Central

25 November 2017

release_s7zftjxchjdrdbav3t5rujez6a

1 reference

https://api.fatcat.wiki/v0/release/s7zftjxchjdrdbav3t5rujez6a

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43662494&oldid=2102376895"